For many people, GLP-1 agonists like Ozempic or Wegovy have been a game-changer for weight loss.

It has long been recognised in the field of obesity research that before these drugs came onto the market, there were very few interventions that worked.

Things have changed fast, so what do you need to know about this new class of drugs if you’re considering taking them?

Guest/s

• Associate Professor Samantha Hocking, endocrinologist at the Royal Prince Alfred Hospital and University of Sydney

References

• Mapping the effectiveness and risks of GLP-1 receptor agonists - Nature